Skip to main content

Table 1 Prognostic factors for DFS and OS of patients with intrahepatic cholangiocarcinoma determined by using univariate and multivariate Cox regression models

From: EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma

Variable

DFS

OS

HR

95% CI

P value

HR

95% CI

P value

Univariate

Sex (women vs. men)

0.820

0.532–1.265

0.370

0.853

0.549–1.324

0.478

Age (<65 years vs. ≥65 years)

1.088

0.659–1.797

0.741

0.984

0.583–1.661

0.953

Liver cirrhosis (yes vs. no)

1.410

0.706–2.816

0.331

1.055

0.508–2.191

0.885

EYA4 protein expressiona (≤3.4 vs. >3.4)

2.635

1.684–4.122

<0.001

2.730

1.727–4.314

<0.001

CA19-9 (>37 U/L vs. ≤37 U/L)

1.753

1.107–2.778

0.017

1.955

1.214–3.147

0.006

CEA (>5 µg/L vs. ≤5 µg/L)

1.665

1.077–2.574

0.022

1.764

1.128–2.758

0.013

Size of tumor (≤5 cm vs. >5 cm)

0.983

0.631–1.529

0.938

1.047

0.667–1.643

0.841

Number of tumors (multiple vs. single)

2.469

1.521–4.006

<0.001

2.921

1.809–4.717

<0.001

Vascular invasion (yes vs. no)

1.803

0.899–3.616

0.097

2.049

1.053–3.989

0.055

Adjacent organ invasion (yes vs. no)

2.489

1.388–4.462

0.002

3.328

1.851–5.984

<0.001

Lymph node metastasis (yes vs. no)

2.410

1.558–3.728

<0.001

2.279

1.460–3.558

<0.001

Tumor differentiation (poor vs. moderate vs. well)

2.009

1.366–2.953

<0.001

2.272

1.540–3.353

<0.001

Multivariate

EYA4 protein expressiona (≤3.4 vs. >3.4)

1.730

1.060–2.823

0.028

1.781

1.093–2.902

0.021

Number of tumors (multiple vs. single)

2.008

1.201–3.357

0.008

2.494

1.508–4.124

<0.001

Adjacent organ invasion (yes vs. no)

2.325

1.238–4.367

0.009

3.765

1.954–7.253

0.001

Lymph node metastasis (yes vs. no)

1.919

1.181–3.120

0.009

1.798

1.106–2.921

0.018

Tumor differentiation (poor vs. moderate vs. well)

2.053

1.301–3.238

0.002

2.530

1.578–4.055

<0.001

  1. EYA4 Eyes absent homolog 4; CA19-9 carbohydrate antigen 19-9; CEA carcino-embryonic antigen; DFS disease-free survival; OS overall survival; HR hazard ratio; CI confidence interval
  2. aImmunohistochemical (IHC) score, split at median